<DOC>
	<DOCNO>NCT01333592</DOCNO>
	<brief_summary>The purpose study evaluate long-term safety efficacy KAD-1229 combination therapy biguanide DPP-4 inhibitor type 2 diabetes patient show inadequate glycemic control diet , biguanide DPP-4 inhibitor monotherapy .</brief_summary>
	<brief_title>Long-term Study KAD-1229 Type 2 Diabetes Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Mitiglinide</mesh_term>
	<criteria>Type 2 diabetes patient show inadequate glycemic control diet , biguanide DPP4 inhibitor monotherapy Age 20 year inclusive HbA1c range â‰¥ 6.5 &lt; 9 % Type 1 diabetes mellitus Patients serious diabetic complication serious complication</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>HbA1c</keyword>
	<keyword>Long-term study</keyword>
</DOC>